{"result": "(\"entity\"<|>AGRANULOCYTOSIS<|>EVENT<|>Agranulocytosis is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a dangerously low white blood cell count.)\n##\n(\"entity\"<|>AMENORRHOEA<|>EVENT<|>Amenorrhoea is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by the absence of menstruation.)\n##\n(\"entity\"<|>ANAEMIA<|>EVENT<|>Anaemia is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a deficiency of red blood cells.)\n##\n(\"entity\"<|>APLASTIC ANAEMIA<|>EVENT<|>Aplastic anaemia is a rare but serious side effect associated with some compounds used to palliate Gilles De La Tourette Syndrome, involving the failure of the bone marrow to produce blood cells.)\n##\n(\"entity\"<|>HAEMOLYTIC ANAEMIA<|>EVENT<|>Haemolytic anaemia is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by the destruction of red blood cells.)\n##\n(\"entity\"<|>ANOREXIA<|>EVENT<|>Anorexia is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a loss of appetite.)\n##\n(\"entity\"<|>ASTHENIA<|>EVENT<|>Asthenia is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a lack of energy or strength.)\n##\n(\"entity\"<|>MENTAL DISORDER<|>EVENT<|>Mental disorder is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, affecting psychological well-being.)\n##\n(\"entity\"<|>BREAST DISORDER<|>EVENT<|>Breast disorder is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, affecting breast tissue.)\n##\n(\"entity\"<|>CHEST PAIN<|>EVENT<|>Chest pain is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, indicating discomfort in the chest area.)\n##\n(\"entity\"<|>ABDOMINAL PAIN<|>EVENT<|>Abdominal pain is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by discomfort in the stomach area.)\n##\n(\"entity\"<|>AGGRESSION<|>EVENT<|>Aggression is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by hostile behavior.)\n##\n(\"entity\"<|>ALOPECIA<|>EVENT<|>Alopecia is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by hair loss.)\n##\n(\"entity\"<|>ANGIOEDEMA<|>EVENT<|>Angioedema is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by swelling beneath the skin.)\n##\n(\"entity\"<|>ANXIETY<|>EVENT<|>Anxiety is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by feelings of worry or fear.)\n##\n(\"entity\"<|>ARRHYTHMIA<|>EVENT<|>Arrhythmia is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by irregular heartbeats.)\n##\n(\"entity\"<|>ARTHRALGIA<|>EVENT<|>Arthralgia is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by joint pain.)\n##\n(\"entity\"<|>ASTHMA<|>EVENT<|>Asthma is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by difficulty in breathing.)\n##\n(\"entity\"<|>FATIGUE<|>EVENT<|>Fatigue is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by extreme tiredness.)\n##\n(\"entity\"<|>FIBROSIS<|>EVENT<|>Fibrosis is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by the thickening and scarring of connective tissue.)\n##\n(\"entity\"<|>GLOSSITIS<|>EVENT<|>Glossitis is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by inflammation of the tongue.)\n##\n(\"entity\"<|>ORTHOSTATIC HYPOTENSION<|>EVENT<|>Orthostatic hypotension is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a sudden drop in blood pressure upon standing.)\n##\n(\"entity\"<|>ABDOMINAL DISTENSION<|>EVENT<|>Abdominal distension is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by swelling in the abdomen.)\n##\n(\"entity\"<|>ABSCESS<|>EVENT<|>Abscess is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a collection of pus in a tissue.)\n##\n(\"entity\"<|>ADENOCARCINOMA<|>EVENT<|>Adenocarcinoma is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a type of cancer that forms in mucus-secreting glands.)\n##\n(\"entity\"<|>ADENOMA BENIGN<|>EVENT<|>Adenoma benign is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a non-cancerous tumor.)\n##\n(\"entity\"<|>ALBINISM<|>EVENT<|>Albinism is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a lack of pigment in the skin, hair, and eyes.)\n##\n(\"entity\"<|>ATAXIA<|>EVENT<|>Ataxia is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by a lack of muscle control or coordination.)\n##\n(\"entity\"<|>NEUROGENIC BLADDER<|>EVENT<|>Neurogenic bladder is a potential side effect associated with several compounds used to palliate Gilles De La Tourette Syndrome, characterized by bladder dysfunction due to nerve damage.)\n##\n(\"relationship\"<|>PIMOZIDE<|>AGRANULOCYTOSIS<|>Agranulocytosis is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>PIMOZIDE<|>AMENORRHOEA<|>Amenorrhoea is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>PIMOZIDE<|>ANAEMIA<|>Anaemia is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>PIMOZIDE<|>APLASTIC ANAEMIA<|>Aplastic anaemia is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>PIMOZIDE<|>HAEMOLYTIC ANAEMIA<|>Haemolytic anaemia is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>PIMOZIDE<|>ANOREXIA<|>Anorexia is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>PIMOZIDE<|>ASTHENIA<|>Asthenia is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>PIMOZIDE<|>MENTAL DISORDER<|>Mental disorder is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>PIMOZIDE<|>BREAST DISORDER<|>Breast disorder is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>PIMOZIDE<|>CHEST PAIN<|>Chest pain is a potential side effect of Pimozide<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>ABDOMINAL PAIN<|>Abdominal pain is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>AGGRESSION<|>Aggression is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>ALOPECIA<|>Alopecia is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>ANGIOEDEMA<|>Angioedema is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>ANXIETY<|>Anxiety is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>ARRHYTHMIA<|>Arrhythmia is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>ARTHRALGIA<|>Arthralgia is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>ASTHMA<|>Asthma is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>FATIGUE<|>Fatigue is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>FIBROSIS<|>Fibrosis is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>GLOSSITIS<|>Glossitis is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>CLONIDINE<|>ORTHOSTATIC HYPOTENSION<|>Orthostatic hypotension is a potential side effect of Clonidine<|>7)\n##\n(\"relationship\"<|>HALOPERIDOL<|>ABDOMINAL DISTENSION<|>Abdominal distension is a potential side effect of Haloperidol<|>7)\n##\n(\"relationship\"<|>HALOPERIDOL<|>ABSCESS<|>Abscess is a potential side effect of Haloperidol<|>7)\n##\n(\"relationship\"<|>HALOPERIDOL<|>ADENOCARCINOMA<|>Adenocarcinoma is a potential side effect of Haloperidol<|>7)\n##\n(\"relationship\"<|>HALOPERIDOL<|>ADENOMA BENIGN<|>Adenoma benign is a potential side effect of Haloperidol<|>7)\n##\n(\"relationship\"<|>HALOPERIDOL<|>ALBINISM<|>Albinism is a potential side effect of Haloperidol<|>7)\n##\n(\"relationship\"<|>HALOPERIDOL<|>ATAXIA<|>Ataxia is a potential side effect of Haloperidol<|>7)\n##\n(\"relationship\"<|>HALOPERIDOL<|>NEUROGENIC BLADDER<|>Neurogenic bladder is a potential side effect of Haloperidol<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>AGRANULOCYTOSIS<|>Agranulocytosis is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>AMENORRHOEA<|>Amenorrhoea is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>ANAEMIA<|>Anaemia is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>APLASTIC ANAEMIA<|>Aplastic anaemia is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>HAEMOLYTIC ANAEMIA<|>Haemolytic anaemia is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>ANOREXIA<|>Anorexia is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>ASTHENIA<|>Asthenia is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>MENTAL DISORDER<|>Mental disorder is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>BREAST DISORDER<|>Breast disorder is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>RISPERIDONE<|>CHEST PAIN<|>Chest pain is a potential side effect of Risperidone<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>AGRANULOCYTOSIS<|>Agranulocytosis is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>AMENORRHOEA<|>Amenorrhoea is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>ANAEMIA<|>Anaemia is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>APLASTIC ANAEMIA<|>Aplastic anaemia is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>HAEMOLYTIC ANAEMIA<|>Haemolytic anaemia is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>ANOREXIA<|>Anorexia is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>ASTHENIA<|>Asthenia is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>MENTAL DISORDER<|>Mental disorder is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>BREAST DISORDER<|>Breast disorder is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERPHENAZINE<|>CHEST PAIN<|>Chest pain is a potential side effect of Perphenazine<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>AGRANULOCYTOSIS<|>Agranulocytosis is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>AMENORRHOEA<|>Amenorrhoea is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>ANAEMIA<|>Anaemia is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>APLASTIC ANAEMIA<|>Aplastic anaemia is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>HAEMOLYTIC ANAEMIA<|>Haemolytic anaemia is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>ANOREXIA<|>Anorexia is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>ASTHENIA<|>Asthenia is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>MENTAL DISORDER<|>Mental disorder is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>BREAST DISORDER<|>Breast disorder is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>PERGOLIDE<|>CHEST PAIN<|>Chest pain is a potential side effect of Pergolide<|>7)\n##\n(\"relationship\"<|>ZIPRASIDONE<|>AGRANULOCYTOSIS<|>Agranulocytosis is a potential side effect of Ziprasidone<|>7)\n##\n(\"relationship\"<|>ZIPRASIDONE<|>AMENORRHOEA<|>Amenorrhoea is a potential side effect of Ziprasidone<|>7)\n##\n(\"relationship\"<|>ZIPRASIDONE<|>ANAEMIA<|>Anaemia is a potential side effect of Ziprasidone<|>7)\n##\n(\"relationship\"<|>ZIPRASIDONE<|>APLASTIC ANAEMIA<|>Aplastic anaemia is a potential side effect of Ziprasidone<|>7)\n##\n(\"relationship\"<|>ZIPRASIDONE<|>HAEMOLYTIC ANAEMIA<|>Haemolytic anaemia is a potential side effect of Ziprasidone<|>7)\n##\n(\"relationship\"<|>ZIPRASIDONE<|>ANOREXIA<|>Anorexia is a potential side effect of Ziprasidone<|>7)\n##\n(\"relationship\"<|>ZIPRASIDONE<|>ASTHENIA<|>Asthenia is a potential side effect of Ziprasidone<|>7)\n##\n(\"relationship\"<|>ZIPRASIDONE<|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: [Gilles De La Tourette Syndrome] is the name of a kind of disease.\n[Gilles De La Tourette Syndrome] presents the symptom [Aerophagy].\n[Gilles De La Tourette Syndrome] presents the symptom [Catalepsy].\n[Gilles De La Tourette Syndrome] presents the symptom [Chorea].\n[Gilles De La Tourette Syndrome] presents the symptom [Dyskinesia, Drug-Induced].\n[Gilles De La Tourette Syndrome] presents the symptom [Dystonia].\n[Gilles De La Tourette Syndrome] presents the symptom [Echolalia].\n[Gilles De La Tourette Syndrome] presents the symptom [Huntington Disease].\n[Gilles De La Tourette Syndrome] presents the symptom [Hyperkinesis].\n[Gilles De La Tourette Syndrome] presents the symptom [Language Disorders].\n[Gilles De La Tourette Syndrome] presents the symptom [Learning Disorders].\n[Gilles De La Tourette Syndrome] localizes at the [Brain] of human body.\n[Gilles De La Tourette Syndrome] localizes at the [Nervous System] of human body.\n[Gilles De La Tourette Syndrome] localizes at the [Central Nervous System] of human body.\n[Gilles De La Tourette Syndrome] localizes at the [Internal Capsule Of Telencephalon] of human body.\n[Gilles De La Tourette Syndrome] localizes at the [Midbrain] of human body.\n[Gilles De La Tourette Syndrome] localizes at the [Cerebellar Nuclear Complex] of human body.\n[Gilles De La Tourette Syndrome] localizes at the [Autonomic Nervous System] of human body.\n\nThe following content describes information about compounds that can palliate or treat the disease named Gilles De La Tourette Syndrome.The format of each compound's information is as follows:\nCompound name: ***\nPharmacologic class: ***\nEffect on Gilles De La Tourette Syndrome: Palliate or Treat\nSide effect: ***\nThese respectively represent the name of the compound, the pharmacologic class it belongs to, its positive effect on the disease named Gilles De La Tourette Syndrome (palliates or treats) and its side effects.\n\nCompound name: Pimozide\nPharmacologic class: None\nEffect on Gilles De La Tourette Syndrome: Palliate\nSide effect: Agranulocytosis, Amenorrhoea, Anaemia, Aplastic anaemia, Haemolytic anaemia, Anorexia, Asthenia, Mental disorder, Breast disorder, Chest pain\n\nCompound name: Olanzapine\nPharmacologic class: None\nEffect on Gilles De La Tourette Syndrome: Palliate\nSide effect: \n\nCompound name: Clonidine\nPharmacologic class: Adrenergic alpha2-Agonists\nEffect on Gilles De La Tourette Syndrome: Palliate\nSide effect: Abdominal pain, Aggression, Alopecia, Angioedema, Anorexia, Anxiety, Arrhythmia, Arthralgia, Asthenia, Asthma\n\nCompound name: Mecamylamine\nPharmacologic class: Decreased Autonomic Ganglionic Activity\nEffect on Gilles De La Tourette Syndrome: Palliate\nSide effect: Anorexia, Asthenia, Chorea, Constipation, Libido decreased, Dizziness, Fatigue, Fibrosis, Glossitis, Orthostatic hypotension\n\nCompound name: Haloperidol\nPharmacologic class: None\nEffect on Gilles De La Tourette Syndrome: Palliate\nSide effect: Agranulocytosis, Alopecia, Amenorrhoea, Anaphylactic shock, Anaemia, Anorexia, Anxiety, Mental disorder, Breast disorder, Bronchospasm\n\nCompound name: Risperidone\nPharmacologic class: None\nEffect on Gilles De La Tourette Syndrome: Palliate\nSide effect: Abdominal distension, Abdominal pain, Abscess, Adenocarcinoma, Adenoma benign, Aggression, Agranulocytosis, Albinism, Alopecia, Amenorrhoea\n\nCompound name: Perphenazine\nPharmacologic class: Phenothiazines\nEffect on Gilles De La Tourette Syndrome: Palliate\nSide effect: Agranulocytosis, Amenorrhoea, Anaphylactic shock, Haemolytic anaemia, Angioedema, Anorexia, Asphyxia, Asthma, Ataxia, Neurogenic bladder\n\nCompound name: Pergolide\nPharmacologic class: Ergot Alkaloids\nEffect on Gilles De La Tourette Syndrome: Palliate\nSide effect: Acute abdomen, Abdominal distension, Abdominal pain, Abscess, Acidosis, Adenoma benign, Alopecia, Amenorrhoea, Amnesia, Anaemia\n\nCompound name: Ziprasidone\nPharmacologic class: None\nEffect on Gilles De La Tourette Syndrome: Palliate\nSide effect: Abdominal pain, Albuminuria, Respiratory alkalosis, Alopecia, Dementia Alzheimer's type, Amblyopia, Amenorrhoea, Amnesia, Anaemia, Hypochromic anaemia\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>GILLES DE LA TOURETTE SYNDROME<|>EVENT<|>Gilles De La Tourette Syndrome is a neurological disorder characterized by involuntary tics and other symptoms affecting the nervous system.)\n##\n(\"entity\"<|>AEROPHAGY<|>EVENT<|>Aerophagy is a symptom associated with Gilles De La Tourette Syndrome, characterized by excessive swallowing of air.)\n##\n(\"entity\"<|>CATALEPSY<|>EVENT<|>Catalepsy is a symptom associated with Gilles De La Tourette Syndrome, involving a trance-like state and muscular rigidity.)\n##\n(\"entity\"<|>CHOREA<|>EVENT<|>Chorea is a symptom associated with Gilles De La Tourette Syndrome, characterized by irregular, unintentional movements.)\n##\n(\"entity\"<|>DYKINESIA, DRUG-INDUCED<|>EVENT<|>Drug-induced dyskinesia is a symptom associated with Gilles De La Tourette Syndrome, resulting from medication side effects.)\n##\n(\"entity\"<|>DYSTONIA<|>EVENT<|>Dystonia is a symptom associated with Gilles De La Tourette Syndrome, involving involuntary muscle contractions.)\n##\n(\"entity\"<|>ECHOLALIA<|>EVENT<|>Echolalia is a symptom associated with Gilles De La Tourette Syndrome, characterized by the involuntary repetition of phrases or words.)\n##\n(\"entity\"<|>HUNTINGTON DISEASE<|>EVENT<|>Huntington Disease is a neurological disorder that can present symptoms similar to those of Gilles De La Tourette Syndrome.)\n##\n(\"entity\"<|>HYPERKINESIS<|>EVENT<|>Hyperkinesis is a symptom associated with Gilles De La Tourette Syndrome, characterized by excessive movement.)\n##\n(\"entity\"<|>LANGUAGE DISORDERS<|>EVENT<|>Language disorders are symptoms associated with Gilles De La Tourette Syndrome, affecting communication abilities.)\n##\n(\"entity\"<|>LEARNING DISORDERS<|>EVENT<|>Learning disorders are symptoms associated with Gilles De La Tourette Syndrome, impacting educational performance.)\n##\n(\"entity\"<|>BRAIN<|>GEO<|>The brain is the organ where Gilles De La Tourette Syndrome localizes, affecting neurological functions.)\n##\n(\"entity\"<|>Nervous System<|>GEO<|>The nervous system is the body system where Gilles De La Tourette Syndrome localizes, controlling bodily functions and movements.)\n##\n(\"entity\"<|>CENTRAL NERVOUS SYSTEM<|>GEO<|>The central nervous system is the part of the nervous system where Gilles De La Tourette Syndrome localizes, including the brain and spinal cord.)\n##\n(\"entity\"<|>INTERNAL CAPSULE OF TELENCEPHALON<|>GEO<|>The internal capsule of the telencephalon is a brain structure where Gilles De La Tourette Syndrome localizes, involved in motor control.)\n##\n(\"entity\"<|>MIDBRAIN<|>GEO<|>The midbrain is a part of the brain where Gilles De La Tourette Syndrome localizes, playing a role in motor movement and auditory processing.)\n##\n(\"entity\"<|>CEREBELLAR NUCLEAR COMPLEX<|>GEO<|>The cerebellar nuclear complex is a brain structure where Gilles De La Tourette Syndrome localizes, involved in coordination and balance.)\n##\n(\"entity\"<|>AUTONOMIC NERVOUS SYSTEM<|>GEO<|>The autonomic nervous system is a part of the nervous system where Gilles De La Tourette Syndrome localizes, regulating involuntary bodily functions.)\n##\n(\"entity\"<|>PIMOZIDE<|>PERSON<|>Pimozide is a compound used to palliate symptoms of Gilles De La Tourette Syndrome, with various side effects.)\n##\n(\"entity\"<|>OLANZAPINE<|>PERSON<|>Olanzapine is a compound used to palliate symptoms of Gilles De La Tourette Syndrome, with unspecified side effects.)\n##\n(\"entity\"<|>CLONIDINE<|>PERSON<|>Clonidine is an adrenergic alpha2-agonist used to palliate symptoms of Gilles De La Tourette Syndrome, with several side effects.)\n##\n(\"entity\"<|>MECAMYLAMINE<|>PERSON<|>Mecamylamine is a compound used to palliate symptoms of Gilles De La Tourette Syndrome, with various side effects.)\n##\n(\"entity\"<|>HALOPERIDOL<|>PERSON<|>Haloperidol is a compound used to palliate symptoms of Gilles De La Tourette Syndrome, with various side effects.)\n##\n(\"entity\"<|>RISPERIDONE<|>PERSON<|>Risperidone is a compound used to palliate symptoms of Gilles De La Tourette Syndrome, with various side effects.)\n##\n(\"entity\"<|>PERPHENAZINE<|>PERSON<|>Perphenazine is a phenothiazine used to palliate symptoms of Gilles De La Tourette Syndrome, with various side effects.)\n##\n(\"entity\"<|>PERGOLIDE<|>PERSON<|>Pergolide is an ergot alkaloid used to palliate symptoms of Gilles De La Tourette Syndrome, with various side effects.)\n##\n(\"entity\"<|>ZIPRASIDONE<|>PERSON<|>Ziprasidone is a compound used to palliate symptoms of Gilles De La Tourette Syndrome, with various side effects.)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>AEROPHAGY<|>Aerophagy is a symptom presented by Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>CATALEPSY<|>Catalepsy is a symptom presented by Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>CHOREA<|>Chorea is a symptom presented by Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>DYKINESIA, DRUG-INDUCED<|>Drug-induced dyskinesia is a symptom presented by Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>DYSTONIA<|>Dystonia is a symptom presented by Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>ECHOLALIA<|>Echolalia is a symptom presented by Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>HUNTINGTON DISEASE<|>Huntington Disease can present symptoms similar to those of Gilles De La Tourette Syndrome<|>4)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>HYPERKINESIS<|>Hyperkinesis is a symptom presented by Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>LANGUAGE DISORDERS<|>Language disorders are symptoms presented by Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>LEARNING DISORDERS<|>Learning disorders are symptoms presented by Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>BRAIN<|>Gilles De La Tourette Syndrome localizes at the brain<|>9)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>Nervous System<|>Gilles De La Tourette Syndrome localizes at the nervous system<|>9)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>CENTRAL NERVOUS SYSTEM<|>Gilles De La Tourette Syndrome localizes at the central nervous system<|>9)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>INTERNAL CAPSULE OF TELENCEPHALON<|>Gilles De La Tourette Syndrome localizes at the internal capsule of telencephalon<|>9)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>MIDBRAIN<|>Gilles De La Tourette Syndrome localizes at the midbrain<|>9)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>CEREBELLAR NUCLEAR COMPLEX<|>Gilles De La Tourette Syndrome localizes at the cerebellar nuclear complex<|>9)\n##\n(\"relationship\"<|>GILLES DE LA TOURETTE SYNDROME<|>AUTONOMIC NERVOUS SYSTEM<|>Gilles De La Tourette Syndrome localizes at the autonomic nervous system<|>9)\n##\n(\"relationship\"<|>PIMOZIDE<|>GILLES DE LA TOURETTE SYNDROME<|>Pimozide is used to palliate symptoms of Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>OLANZAPINE<|>GILLES DE LA TOURETTE SYNDROME<|>Olanzapine is used to palliate symptoms of Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>CLONIDINE<|>GILLES DE LA TOURETTE SYNDROME<|>Clonidine is used to palliate symptoms of Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>MECAMYLAMINE<|>GILLES DE LA TOURETTE SYNDROME<|>Mecamylamine is used to palliate symptoms of Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>HALOPERIDOL<|>GILLES DE LA TOURETTE SYNDROME<|>Haloperidol is used to palliate symptoms of Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>RISPERIDONE<|>GILLES DE LA TOURETTE SYNDROME<|>Risperidone is used to palliate symptoms of Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>PERPHENAZINE<|>GILLES DE LA TOURETTE SYNDROME<|>Perphenazine is used to palliate symptoms of Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>PERGOLIDE<|>GILLES DE LA TOURETTE SYNDROME<|>Pergolide is used to palliate symptoms of Gilles De La Tourette Syndrome<|>8)\n##\n(\"relationship\"<|>ZIPRASIDONE<|>GILLES DE LA TOURETTE SYNDROME<|>Ziprasidone is used to palliate symptoms of Gilles De La Tourette Syndrome<|>8)\n<|COMPLETE|>"}]}